Section Arrow
PEPG.NASDAQ
- PepGen
Quotes are at least 15-min delayed:2025/07/16 04:34 EDT
Pre Market
Last
 --
-- (--)
Bid
1
Ask
1.37
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 1.24
-0.05 (-3.88%)
Day High 
1.32 
Prev. Close
1.29 
1-M High
1.49 
Volume 
136.96K 
Bid
1
Ask
1.37
Day Low
1.22 
Open
1.29 
1-M Low
1.05 
Market Cap 
42.21M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.19 
20-SMA 1.29 
50-SMA 1.4 
52-W High 19.298 
52-W Low 0.8801 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.14/-2.63
Enterprise Value
57.78M
Balance Sheet
Book Value Per Share
2.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KAPAKairos Pharma Ltd.1.17+0.4849+70.78%-- 
Pre Market 0.9243 -0.2457 -21.00%
NCNANuCana plc0.0502+0.0043+9.37%-- 
Pre Market 0.0506 +0.0004 +0.80%
PLRZPolyrizon Ltd1.04+0.3579+52.47%-- 
Pre Market 0.92 -0.12 -11.54%
CYCCCyclacel Pharmaceuticals Inc12.33+9.02+272.51%0.08PE
Pre Market 7.7 -4.63 -37.55%
IOVAIovance Biotherapeutics1.94-0.07-3.48%-- 
Pre Market 1.92 -0.02 -1.03%
Quotes are at least 15-min delayed:2025/07/16 04:34 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it isobserved their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.